Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Non-Transfusion-dependent Alpha-Thalassemia
Clinical Trial
NCT04770753Last updated: 12/4/2025
Pyrukynd
Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4).
